Evidence map›Paper›PMID 35746663›Full record

ArticleViruses2022

Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme.

Egle Ciupkeviciene, Janina Petkeviciene, Jolanta Sumskiene, Gediminas Dragunas, Saulius Dabravalskis, Edita Kreivenaite, Tadas Telksnys, Gediminas Urbonas, Limas Kupcinskas

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Egle CiupkevicieneHealth Research Institute, Faculty of Public Health, Lithuanian University of Health Sciences, LT47181 Kaunas, Lithuania.
Janina PetkevicieneHealth Research Institute, Faculty of Public Health, Lithuanian University of Health Sciences, LT47181 Kaunas, Lithuania.ORCID 0000-0002-3953-8655
Jolanta SumskieneDepartment of Gastroenterology, Lithuanian University of Health Sciences, LT50161 Kaunas, Lithuania.
Gediminas DragunasJurininku Health Care Centre, LT91213 Klaipeda, Lithuania.
Saulius DabravalskisJurininku Health Care Centre, LT91213 Klaipeda, Lithuania.
Edita KreivenaiteDepartment of Gastroenterology, Lithuanian University of Health Sciences, LT50161 Kaunas, Lithuania.
Tadas TelksnysHealth Research Institute, Faculty of Public Health, Lithuanian University of Health Sciences, LT47181 Kaunas, Lithuania.
Gediminas UrbonasDepartment of Family Medicine, Lithuanian University of Health Sciences, LT50161 Kaunas, Lithuania.
Limas KupcinskasDepartment of Gastroenterology, Lithuanian University of Health Sciences, LT50161 Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2022, the Lithuanian health authorities decided to pay general practitioners a fee for performing serological tests for hepatitis C virus (HCV) antibodies in the population born from 1945 to 1994 once per life and annual HCV testing for PWID and HIV infected patients. This study aimed to assess trends in HCV-related mortality in the country and the prevalence of HCV infection among patients with liver diseases and evaluate possibilities of screening for HCV infection at a primary health care center. Age-standardized mortality rates in 2010-2020 were calculated for deaths caused by chronic hepatitis C and some liver diseases. Data on HCV infection among patients with liver cirrhosis, cancer and transplant patients were collected from the tertiary care hospital Kauno Klinikos. The prevalence of anti-HCV and risk factors of HCV infection was assessed among patients registered with the health care center in Klaipeda, where a pilot study of screening was performed. No steady trend in mortality was observed. Analysis of medical documentation showed that 40.5% of patients with liver cirrhosis, 49.7% with cancers and 36.9% of transplant patients were HCV infected. Over the year, 4867 patients were screened in the primary health care center. Positive anti-HCV prevalence was 1.7% (2.1% in men and 1.3% in women). Blood transfusion and being a blood donor before 1993 also having tattoos were associated with higher odds of HCV infection. The study revealed the active participation of individuals in HCV screening.

Indexed as

HepacivirusHepatitis CFemaleHepatitis C AntibodiesHumansLithuaniaLiver CirrhosisMalePilot ProjectsPrevalenceHepatitis C AntibodiesepidemiologyHCVhepatitisrisk factorsscreening

Identifiers

PMID35746663
PMCPMC9230764
OpenAlexW4283454866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.